8.45
-0.71%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Getein Biotech
Its shares trade on Shanghai under the ticker 603387.SS. It has been listed since 17 July 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.05bn and net income of CN¥220.7m. At that date it held total assets of CN¥3.76bn and shareholders' equity of CN¥2.75bn.
Getein Biotech, Inc. engages in the business of medical health industry chain. The company is headquartered in Nanjing, Jiangsu. The company went IPO on 2017-07-17. Its in vitro diagnostic reagents include Point-of-care Testing (POCT) reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, hemagglutination reagents and others. Its diagnostic instruments include immunoquantitative analyzer FIA 8000, immunoquantitative analyzer FIA 8600, fluorescence immunoquantitative analyzer Getein 1100, fluorescence immunoquantitative analyzer Getein 1180, automatic biochemical analyzer CM 400, automatic chemiluminescence analyzer MAGICL 6000 and five classification blood cell analyzer BHA-5000, among others. The firm also provides testing and agency services. The firm distributes its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Jul 2017
- Employees
- 2,508
- Website
- getein.com.cn ↗
Leadership
Pay as last reported
- Mr. Enben SuChairman of the Board, General Manager, since 2014CN¥138,600
- Mr. Wen NiChief Financial Officer, Director, since 2017CN¥568,000
- Ms. Tingting KongDeputy General Manager, Director, since 2018CN¥680,000
- Mr. Bin YanDeputy General Manager, Director, since 2014CN¥775,500
- Ms. Cong LiuSecretary of the BoardCN¥342,500
- Mr. Enkui SuDirectorCN¥389,800
- Ms. Aidi TaoDirector
- Mr. Jixian JuIndependent Director
- Ms. Hua LingIndependent Director
- Mr. Suiren WanIndependent DirectorCN¥100,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Nanjing, Jiangsu with 2,508 employees
- Offers a diverse range of in vitro diagnostic reagents including POCT, chemiluminescence, and biochemical reagents
- Provides diagnostic instruments such as immunoquantitative analyzers and automatic biochemical analyzers
Weaknesses
- No specific weaknesses mentioned in the provided information
- No details on financial performance or market share provided
- No information on competitive advantages or unique technologies
Opportunities
- Expansion into overseas markets for product distribution
- Growth potential in the medical health industry chain sector
- Potential for increased demand in diagnostic reagents and instruments
Threats
- No specific threats mentioned in the provided information
- No details on regulatory challenges or market competition
- No information on economic or geopolitical risks affecting operations
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.